Key facts
- This page summarizes Darrell Shane Lea's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Dec 2023, 20:09.
Darrell Shane Lea - 23 Jun 2023 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- CLRB
- Reported as of
- 23 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Dec 2023, 20:09:39 UTC
- Prior SEC filing
- 15 Dec 2022
- Next SEC filing
- 18 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christina Blakley, Attorney in-fact for Darrell Shane Lea
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Darrell Shane Lea filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 12 Dec 2023.
Change
- Previous filing in this sequence was filed on 15 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLRB
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +39,599
- Change %
- Price
- $0.000000
- Shares after
- 39,599
- Date
- 08 Dec 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLRB
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 23 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.68
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option was contingently granted on January 16, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2023 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 23, 2023. Because January 16, 2023 was a federal holiday, the option was priced on the following trading day.
Footnote F2
This option shall vest over a period of three years from January 17, 2023, with 1/3 vesting on the first anniversary of January 17, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of January 17, 2023.